4DMEDICAL ORD
4DMedical Secures CT:VQ Imaging Commitment Through Expanded Philips Distribution Deal
4DMedical (ASX: 4DX) has secured a minimum US$10 million (A$15m) order commitment for its FDA-approved CT:VQ imaging solution under an expanded distribution agreement with multinational giant Philips.
4DMedical Extends Imaging Technology into Public Hospitals and National Screening Network
4DMedical (ASX: 4DX) has secured three significant agreements to expand the reach of its lung health imaging technology. In Australia, 4DMedical has locked in a multi-year deal with Spectrum Medical Imaging to support the National Lung Cancer Screening Program. The company will also launch a Brazilian lung screening program with a leading pharmaceutical partner, while […]
4DMedical Secures US Medicare Reimbursement Approval for CT:VQ Imaging Software
4DMedical (ASX: 4DX) has received reimbursement approval from the US Centers for Medicare & Medicaid Services (CMS) for its CT:VQ lung imaging platform. The decision follows Food and Drug Administration (FDA) clearance granted last week, aligning regulatory authorisation with a defined payment structure. Together, the approvals clear the path for commercial rollout of the software […]
4DMedical Gains FDA Clearance For Groundbreaking CT:VQ Imaging Software
4DMedical (ASX: 4DX) has received United States Food and Drug Administration (FDA) clearance for its CT:VQ software, marking a major milestone in respiratory diagnostics. The technology is the world’s first non-contrast CT-based ventilation-perfusion tool to replace nuclear medicine scans currently used to assess airflow and blood flow in the lungs. The clearance opens a potential […]